Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 93.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,982 shares of the company's stock after selling 454,246 shares during the period. Ameriprise Financial Inc.'s holdings in Syndax Pharmaceuticals were worth $423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC increased its holdings in Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock valued at $3,612,000 after purchasing an additional 110,535 shares during the last quarter. Jump Financial LLC increased its holdings in Syndax Pharmaceuticals by 80.8% in the 4th quarter. Jump Financial LLC now owns 173,890 shares of the company's stock valued at $2,299,000 after purchasing an additional 77,699 shares during the last quarter. Simplify Asset Management Inc. increased its holdings in Syndax Pharmaceuticals by 20.8% in the 4th quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company's stock valued at $1,952,000 after purchasing an additional 25,456 shares during the last quarter. Northern Trust Corp increased its holdings in Syndax Pharmaceuticals by 7.5% in the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after purchasing an additional 55,144 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Syndax Pharmaceuticals by 594.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 331,300 shares of the company's stock valued at $4,378,000 after buying an additional 283,577 shares during the period.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Citigroup decreased their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Scotiabank raised their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $35.91.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock traded up $0.29 during trading on Friday, hitting $11.45. 1,341,845 shares of the stock were exchanged, compared to its average volume of 1,797,386. The stock has a market cap of $985.24 million, a price-to-earnings ratio of -3.15 and a beta of 0.74. The firm's 50-day moving average price is $11.32 and its 200 day moving average price is $13.23. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. During the same period last year, the firm posted ($0.85) earnings per share. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% on a year-over-year basis. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).